Thane Hospital Theft: Rs 21 Lakh Stolen, 3 Arrested

Thane: In a significant development, the Thane police have arrested three individuals, including two former employees of a private hospital, for allegedly stealing ₹21 lakh from a doctor’s cabin. 

The theft occurred on September 21 at a medical facility in Vinay Nagar, Kashigaon, where the doctor discovered the burglary upon returning to his cabin. This incident raises serious concerns about security within healthcare facilities, highlighting the vulnerabilities that medical institutions face despite their commitment to providing essential services to the community.

Also Read:Maharashtra Doctor robbed of Rs 82 Lakhs, five guards arrested

According to the PTI report, after the doctor discovered his cabin ransacked and a substantial amount of cash missing, Kashigaon police station’s Senior Inspector Rahulkumar Patil stated that police reviewed CCTV footage. This footage revealed an unidentified masked individual entering the cabin and stealing the money.

Authorities have indicated that the investigation revealed the suspects likely had insider knowledge of the hospital’s cash handling processes. This has led law enforcement to scrutinize the backgrounds of employees and associates connected to the hospital, as they seek to uncover any potential accomplices or further vulnerabilities in the system.

Following the shocking theft of ₹21 lakh from a Thane hospital, police have made significant progress in the case by apprehending the doctor’s former driver, a 28-year-old resident of Katihar, Bihar, who wore a mask during the theft. Additionally, a 34-year-old accomplice from Uttar Pradesh was also arrested.

The investigation, which began with the arrest of a 32-year-old former employee from Pratapgarh, revealed crucial details about the crime. As a result of these efforts, police recovered ₹18 lakh of the stolen cash, along with an auto-rickshaw, a mask, and various tools used in the commission of the theft.

A case has been filed against the three individuals under relevant sections of the Bharatiya Nyaya Sanhita. The swift action by the police underscores their commitment to addressing crime and ensuring justice in the community.

Also Read: Maharashtra Doctor robbed of Rs 9.5 Lakh, Tadipar thief caught on camera

Powered by WPeMatico

Tension erupts at Thiruvananthapuram SAT Hospital after 3-hour power outage, Probe ordered

Kerela: Kerala Health Minister Veena George has ordered a probe following complaints about a nearly three-hour power outage at the state-run Sree Avittam Thirunal (SAT) Hospital in Thiruvananthapuram on Sunday night. The incident led to heated exchanges between the families of patients and hospital authorities.

Family members of patients admitted to the state-run Sree Avittam Thirunal Hospital (SAT) Hospital here protested outside the gate as some blocks in the facility faced a power outage for nearly three hours on Sunday night. The hospital, located on the Government Medical College campus, witnessed heated arguments between the family members of the patients and hospital authorities. 

According to the PTI report, taking cognizance of the matter, Health Minister Veena George said a comprehensive technical committee will carry out a probe into the power outage reported in one of the blocks in the hospital.

Also Read:Mob Attack: Junior doctors, nurses at Sagore Dutta Hospital attacked after patient’s death, Colleagues go on strike

When the incident was brought to her notice, George also sought the emergency support of the power minister and the electrical wing of the Public Works Department (PWD) to restore the power supply.  

As the tension escalated, more police personnel were deployed on the hospital campus. The power supply was restored after nearly three hours.  

SAT Hospital is a tertiary care institute, the maternal and child health wing of Government Medical College here.

As the protest mounted, the Kerala Electricity Board Limited (KSEB) claimed that the power outage was not because of any fault from their side.

Meanwhile, Leader of Opposition in the state Assembly V D Satheesan criticised the government over the issue and accused the Health Department of not paying heed to the matter, news agency PTI reported.

The power supply was interrupted for over three hours and it was restored temporarily after intense protests staged by patients and their family members, he said.

He also criticised the authorities for not shifting pregnant women and newborn babies, admitted there in critical condition, to other hospitals.

In a statement, the LoP also demanded a comprehensive probe into the incident, adds PTI.

Also Read:RG Kar PG Medico Death Case: Govt Medical Colleges Enhance Safety Amid Protests

Powered by WPeMatico

Gefarnate Enhances Lipid Control in Statin-Treated CAD Patients with High Triglycerides, Study Finds

China: In a randomized controlled trial, researchers have uncovered significant lipid-lowering benefits of gefarnate when added to statin therapy in older adults with coronary artery disease (CAD) suffering from residual hypertriglyceridemia. The study, published in the Journal of Geriatric Cardiology, highlights the potential of gefarnate to enhance lipid profiles and mitigate gastrointestinal side effects often associated with standard treatments.

Preventing CAD comes with two major challenges: gastrointestinal problems caused by aspirin and ongoing heart risks even after taking statins. Gefarnate, an anti-ulcer medication, may help address these issues. Research suggests that geraniol, a component of gefarnate, could play a role in managing lipid levels in the body through different processes. Considering this, Guang-Zhong LIU, Department of Cardiology, Shenzhen People’s Hospital, Shenzhen, China, and colleagues aimed to evaluate how gefarnate affects lipid levels in CAD patients already on statin treatment but still have high triglyceride levels.

For this purpose, the researchers conducted a prospective, open-label, randomized controlled trial involving 69 statin-treated CAD patients with high triglyceride levels. Participants were randomly assigned to either the gefarnate group or the control group. Those in the gefarnate group received 100 mg of gefarnate three times a day alongside their statin, while the control group received only the statin.

The researchers measured plasma levels of triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and total cholesterol at the beginning of the study and after one month of treatment.

The study led to the following findings:

  • After one-month gefarnate treatment, triglyceride level was significantly lowered from 2.64 mmol/L to 2.12 mmol/L, LDL-C level reduced from 2.7 mmol/L to 2.37 mmol/L, HDL-C level increased from 0.97 mmol/L to 1.17 mmol/L.
  • Based on statin therapy, gefarnate could significantly reduce the plasma triglyceride level and increase the plasma HDL-C level.
  • Although the LDL-C and total cholesterol levels tended to decrease, there was no statistically significant difference.

Our study had limitations: it was open-label with a small sample size and short follow-up. The long-term effects of gefarnate on lipid levels and cardiovascular risk need further research.

In conclusion, the researchers conducted a randomized controlled study to examine the lipid-lowering benefits of gefarnate in CAD patients on statin therapy with residual hypertriglyceridemia and its safety.

“Our findings indicated that gefarnate effectively reduced plasma triglycerides and increased HDL-C levels. We hope this study offers insights into the potential role of gefarnate in treating dyslipidemia and lowering residual cardiovascular risk,” the researchers concluded.

“The investigators believe this study will offer important insights into gefarnate’s potential role in treating dyslipidemia and reducing residual cardiovascular risk,” they stated. 

Reference:

SHI J, XU M-L, HE M-J, et al. Lipid-lowering effects of gefarnate in statin-treated patients with residual hypertriglyceridemia: a randomized controlled study. Journal of Geriatric Cardiology, 2024, 21(8): 791-798. https://doi.org/10.26599/1671-5411.2024.08.001

Powered by WPeMatico

GLP-1 Receptor Agonists Reduce Hyperkalemia and Enhance RASi Use in Type 2 Diabetes

Results of a recent study found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a lower risk for hyperkalemia, greater persistence with renin-angiotensin system inhibitors, in patients with type-2 diabetes (T2D). A research letter by Tao Huang and colleagues was published online recently in JAMA Internal Medicine. Thus, GLP-1RAs appear to bypass one of the common barriers that complicate effective therapy for diabetes and may improve clinical outcomes.

This is of important concern for T2D patients, especially those who use RAS inhibitors to manage blood pressure and preserve kidney function as part of their treatment. The risk of developing hyperkalemia could lead to underutilization of these guideline-recommended medications. Of interest, recent evidence has suggested that GLP-1RAs—a newer class of diabetes medications—may increase urinary potassium excretion, thereby decreasing the risk of developing hyperkalemia.

This was a cohort study of data from adults with T2D newly initiated on either GLP-1RAs or DPP-4is in Stockholm, Sweden, from January 1, 2008, to December 31, 2021. Data analysis took place from October 1, 2023, to April 29, 2024. A total of 33,280 participants were used, including 13,633 users of GLP-1RA and 19,647 users of DPP-4i. Rates of hyperkalemia, defined as potassium above 5.0 mEq/L, and moderate-to-severe hyperkalemia, defined as a potassium level above 5.5 mEq/L, were the measured major outcomes. The secondary outcome measured was the rate of discontinuation of RASi therapy among users at baseline. Inverse probability of treatment weight was applied to balance over 70 confounders, and marginal structural models were used to estimate hazard ratios.

Key Findings

  • The use of GLP-1RAs was associated with a lower rate of any hyperkalemia compared to DPP-4is (HR, 0.61; 95% CI, 0.50-0.76).

  • For moderate to severe hyperkalemia, GLP-1RAs also showed a significant reduction (HR, 0.52; 95% CI, 0.28-0.84).

  • Among the 21,751 participants who were on RASis at the start of the study, 1,381 discontinued this therapy.

  • GLP-1RA use was linked to a lower rate of RASi discontinuation compared to DPP-4i use (HR, 0.89; 95% CI, 0.82-0.97).

  • The results were consistent across different age groups, sexes, cardiovascular comorbidities, and baseline kidney function.

The findings suggest that GLP-1RAs could be expected to lower the likelihood of hyperkalemia and thereby enable the continued administration of RAS inhibitors, which play a key role in managing blood pressure and preserving kidney function in T2D patients. This being the case, in reducing the rate of hyperkalemia and promoting continued RAS use, GLP-1RAs might also optimize the total control of diabetes and hence improve patient outcomes in a more general way.

Finally, as compared to DPP-4is, GLP-1RAs were associated with lower rates of hyperkalemia and better persistence with RASi therapy. It became even more speculative in this analysis whether GLP-1RAs played such a critical role in T2D treatment since they could overcome barriers to a certain level and possibly improve clinical outcomes.

Reference:

Huang, T., Bosi, A., Faucon, A.-L., Grams, M. E., Sjölander, A., Fu, E. L., Xu, Y., & Carrero, J. J. (2024). GLP-1RA vs DPP-4i use and rates of hyperkalemia and RAS blockade discontinuation in type 2 diabetes. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2024.3806

Powered by WPeMatico

Predictive Biomarkers May Support Potential for “Personalized Medicine Approach” in RA Patients, Study Reveals

A study published by researchers in Trinity College Dublin and St Vincent’s University Hospital proposes a better understanding of the site of inflammation in rheumatoid arthritis which will allow for the development of new treatment strategies or predictive biomarkers which could support the potential for a ‘personalised medicine’ approach. The study was published in the journal Science Advances. In India, the prevalence of rheumatoid arthritis is estimated to be 0.7% which is higher than the global prevalence of 0.46%

The team performed an in-depth investigation of a specific population of cells: ‘the macrophages’ that reside in the synovium of Rheumatoid arthritis patients, ‘individuals-at-risk’ of RA, and healthy controls. Researchers demonstrated for the first time, the presence of a dominant macrophage subtype (CD40-expressing CD206+CD163+) in the inflamed Rheumatoid arthritis synovium, which importantly was associated with disease activity and treatment response.
The team identified that these cells are resident in the joint which, in health plays a protective role, but in disease – for reasons we are unsure of – become pro-inflammatory, and release proteins called cytokines that induce inflammation, and also can activate the invasive fibroblast cell type which leads to cartilage and bone destruction.
Researchers identified that the pro-inflammatory status of these macrophages is maintained by specific signaling and metabolic pathways within the joint, the targeting of which may induce the resolution of inflammation. Importantly the team identified that these changes in the macrophage status occurred pre-disease onset.
Combined, these findings identify the presence of an early pathogenic macrophage cell/gene signature that shapes the Rheumatoid arthritis joint inflammatory environment and represents a unique opportunity for early diagnosis and therapeutic intervention.
Reference: Loss of synovial tissue macrophage homeostasis precedes rheumatoid arthritis clinical onset. https://www.science.org/doi/epdf/10.1126/sciadv.adj1252

Powered by WPeMatico

Bilateral mastectomy effective in preventing contralateral spread for unilateral breast cancer patients: Study

A new study published in the Journal of American Medical Association shows that despite contralateral mastectomy is a successful cancer preventive strategy for unilateral breast cancer, it does not lower the chance of breast cancer-related death or raise concerns about the possibility of a de novo contralateral cancer spreading.

Bilateral mastectomy is the treatment of choice for many women with unilateral breast cancer because it is believed to be the most effective way to stop the growth of another breast tumor and lower their chance of mortality. This study indicated that removing an undamaged breast lowers the risk of developing a second breast cancer, but no studies have shown that this lowers the death rate from breast cancer. Thus, this study by Vasily Giannakeas and colleagues was set to calculate the 20-year cumulative risk of breast cancer mortality in women who had unilateral breast cancer ranging from stage 0 to stage III based on the kind of first surgery that was done.

This cohort analysis identified women diagnosed between 2000 and 2019 with unilateral breast cancer (invasive and ductal carcinoma in situ) using the Surveillance, Epidemiology and End Results (SEER) Program registry database. Using 1:1:1 matching, three tightly matched cohorts of similar size were produced based on the surgical technique. For 20 years, the cohorts were monitored for breast cancer mortality and contralateral breast cancer. The 20-year cumulative risk of breast cancer mortality for women treated with lumpectomy versus unilateral mastectomy or bilateral mastectomy was evaluated in the research.

A total of 661,270 women with unilateral breast cancer were included in the research sample. Following matching, the three treatment groups comprised close to 36,028 women respectively.

20-year follow-up revealed 766 contralateral breast cancers in the group that had a lumpectomy, 728 contralateral breast cancers in the group that had a unilateral mastectomy and 97 contralateral cancers in the group that had a bilateral mastectomy. In the lumpectomy-unilateral mastectomy group, the 20-year risk of contralateral breast cancer was 6.9%.

By 15 years following the development of a contralateral cancer, the cumulative breast cancer mortality was 32.1% and for the individuals who did not get a contralateral cancer, it was 14.5%. 37 women in the lumpectomy group, 36 women in the unilateral mastectomy category and 36 women in the bilateral mastectomy category died of breast cancer.

Overall, bilateral mastectomy lowered the risk of contralateral breast cancer when compared to other surgical treatments. The outcomes of this research found no difference in mortality between bilateral mastectomy, lumpectomy, and unilateral mastectomy.

Reference:

Giannakeas, V., Lim, D. W., & Narod, S. A. (2024). Bilateral Mastectomy and Breast Cancer Mortality. In JAMA Oncology. American Medical Association (AMA). https://doi.org/10.1001/jamaoncol.2024.2212

Powered by WPeMatico

FINEARTS-HF Trial: Finerenone Offers Significant Benefits for HF Patients Following Recent Worsening Events

USA: The FINEARTS-HF trial revealed that the benefit-risk profile of finerenone (Kerendia) for heart failure with mildly reduced or preserved ejection fraction (HFmrEF, HFpEF) remained largely unaffected by delayed initiation. The findings were published online in the Journal of the American College of Cardiology. 

“An analysis of the time since a patient’s worsening heart failure (WHF) event indicated that the efficacy of finerenone in reducing the primary composite outcome was most pronounced when patients were enrolled within seven days of the WHF event (relative risk [RR] 0.74 compared to placebo). The effectiveness decreased as time elapsed, reaching a nonsignificant low for those enrolled more than three months after the WHF event (RR 0.99),” the researchers reported. However, this observed pattern did not achieve statistical significance as a treatment-by-time interaction.

Patients with heart failure (HF) who have experienced a recent worsening heart failure event are recognized as being at a significantly increased risk of recurrent hospitalization and mortality, regardless of their ejection fraction. Considering this, Akshay S. Desai, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA, and colleagues aimed to investigate the safety and efficacy of the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone with the recency of a WHF event.

FINEARTS-HF trial was a randomized, double-blind, placebo-controlled study assessing finerenone in patients with heart failure and a left ventricular ejection fraction of ≥40%. In the prespecified analysis, the researchers evaluated the risk of cardiovascular (CV) events and the response to finerenone compared to placebo, focusing on the time interval from WHF to randomization (during or within seven days, seven days to 3 months, over three months, or with no prior WHF). The primary outcome was a composite of total (first and recurrent) WHF events and CV death, analyzed using a proportional rates method.

Based on the study, the researchers reported the following findings:

  • Of 6,001 patients validly randomized to finerenone or placebo, 20.3% were enrolled during (12.5%) or within seven days (7.8%), 33.8% between 7 days and three months, and 15.6% >3 months from a WHF event; 30.3% had no prior history of WHF.
  • Rates of the primary composite outcome varied inversely with time since WHF, with >2-fold higher risk in those enrolled during or within seven days of WHF compared with those enrolled >3 months from WHF or without prior WHF (risk ratio [RR]: 2.13).
  • Compared to placebo, finerenone appeared to lower the risk of the primary composite to a greater extent in those enrolled within seven days of WHF (RR: 0.74) or between 7 days and three months of WHF (RR: 0.79) than in those >three months from WHF or without prior WHF (RR: 0.99); however, no definitive treatment-by-time interaction could be confirmed.
  • Greater absolute risk reductions with finerenone were accordingly seen in those with recent WHF.
  • The risk of adverse events, including hyperkalemia and worsening renal function, among patients assigned to finerenone did not increase in those with recent WHF.

The findings showed that patients with HFmrEF or HFpEF who experience a worsening heart failure event—regardless of the treatment setting—are at a higher risk for subsequent hospitalizations and mortality compared to those without a recent WHF event. However, they seem to benefit more significantly from finerenone.

“Since the risk of adverse events associated with finerenone does not appear to increase in individuals with recent WHF, and the absolute risk reductions are greater, this population could be an especially promising target for using finerenone in clinical practice,” the researchers concluded.

Reference:

Desai A, et al “Finerenone in patients with a recent worsening heart failure event: The FINEARTS-HF trial” J Am Coll Cardiol 2024; DOI: 10.1016/j.jacc.2024.09.004.

Powered by WPeMatico

FK506 with rapamycin could effectively improve renal transplantation prognosis, suggests study

A new study published in the journal of BMC Nephrology suggests that FK506 and rapamycin may be able to enhance the outcome of kidney transplantation by lowering interstitial fibrosis, vascular inflammation, and ultimately transplanted kidney rejections.

Over time, chronic kidney disease (CKD) has grown to be a serious worldwide health issue. About 130 million individuals in China suffer from CKD, of which the prevalence is 10.8%. Of them, 1-2% eventually develop end-stage renal disease (ESRD). Replacement treatment, such as peritoneal dialysis, hemodialysis, and allograft kidney transplantation (KTx), is currently the mainstay of care for ESRD patients. Patients are nonetheless suffering from late allograft failure despite significant advancements over the previous few decades. Many variables that impact the prognosis of kidney transplant patients have been widely documented globally in recent years. These variables include recipient baseline data, surgical outcomes, immunosuppressive regimes, and more. Therefore, Yisheng Ji and colleagues undertook this study to assess the impact of rapamycin and the long-term renal transplant prognosis from a single-center in China throughout a 30-year follow-up.

A total of 654 individuals who received kidney transplants between 1989 and 2020 were included in this research. The fundamental attributes of the patients that were involved were gathered. K-M curves, or Kaplan-Meier curves, were employed to compare and characterize graft survival. A multivariate Cox proportional-hazards model had both continuous and categorical variables. The patients were split into two groups, namely the traditional tacrolimus-based triple immunosuppression regimen group (n = 218), and the rapamycin-based quadruple immunosuppression regimen group (n = 41). The frequency of rejection, acute rejection, and banff score were compared between the indication biopsy findings of the two groups.

After surgery, the median survival period is 14 years. Risk variables for diabetes, immunosuppressants, globulin, urine albumen, blood glucose, and BMI were found using multiple Cox regression analysis. The model also revealed that rapamycin and FK506 together might significantly improve the transplant prognosis.

The overall survival rate of renal grafts in the rapa group was considerably higher than that in the traditional group, as indicated by the K-M curve. Also, the biopsy records showed that the rapa group had a reduced risk of immunological rejection than the standard group did. According to the Banff score, the transplanted kidney of the rapa group showed decreased vascular inflammation. Overall, the predictive model and subgroup analysis revealed that FK506 paired with rapamycin might significantly enhance the prognosis of kidney transplantation, which could be attributed to decreased acute rejection and vascular inflammation.

Source:

Ji, Y., Sun, L., Fei, S., Gao, X., Chen, H., Han, Z., Tao, J., Ju, X., Wang, Z., Tan, R., & Gu, M. (2024). Long-term outcomes in rapamycin on renal allograft function: a 30-year follow-up from a single-center experience. BMC Nephrology, 25(1), 1–10. https://doi.org/10.1186/s12882-024-03730-8

Powered by WPeMatico

Oral bisphosphonate, periodontitis, diabetes and super-hydrophilic implant surface tied to peri-implant MBL: Study

Oral bisphosphonate intake, periodontitis, diabetes and super-hydrophilic implant surface tied to peri-implant MBL suggests a study published in the Clinical Oral Implants Research.

A study was done to evaluate the influence of patient and implant-related factors on the changes in marginal bone levels (MBL) at implants with a follow-up ≥5 years. At baseline (within 6 months from prosthetic insertion) and long-term (≥5 years after implant placement) visits, interproximal (mesial and distal) MBL were radiographically evaluated. To analyze factors predicting MBL change, the site (either mesial or distal) showing the highest MBL change (hChMBL site) was identified for each implant. Multilevel regression models were built to explain MBL change as well as the probability for a bone loss ≥2 mm at long-term. Results: 942 implants in 312 patients with a mean follow-up of 8.02 ± 2.5 years were analyzed. MBL change was significantly predicted by baseline MBL, oral bisphosphonate (BP) intake, history of periodontitis, diabetes, and super-hydrophilic implant surface. Higher risk for a bone loss ≥2 mm was observed in patients with history of periodontitis (OR = 9.52, 95% CI 0.72–3.79) and taking BP (OR = 6.84, 95% CI 0.21–3.63). Mandibular implants had higher odds for bone loss ≥2 mm compared to maxillary implants (OR = 3, 95% CI 0.39–1.87). The findings of the present study contribute to the identification of specific clinical scenarios at higher risk for implant-supporting bone loss that need to be strictly monitored during maintenance

Reference:

Trombelli, L., Farina, R., Tomasi, C., Vignoletti, F., Paolantoni, G., Giordano, F., Ortensi, L., & Simonelli, A. (2024). Factors affecting radiographic marginal bone resorption at dental implants in function for at least 5 years: A multicenter retrospective study. Clinical Oral Implants Research, 00, 1–12. https://doi.org/10.1111/clr.14327

Keywords:

Oral, bisphosphonate, intake, periodontitis, diabetes, super-hydrophilic, implant surface, peri-implant MBL, Study, Trombelli, L., Farina, R., Tomasi, C., Vignoletti, F., Paolantoni, G., Giordano, F., Ortensi, L., & Simonelli, A

Powered by WPeMatico

Partial tonsillectomy as effective as total tonsillectomy for patients with recurrent tonsillitis, finds study

Partial tonsillectomy as effective as total tonsillectomy for patients with recurrent tonsillitis, finds a study published in the European Archives of Oto-Rhino-Laryngology.

In long-term follow-up, it remains uncertain whether tonsillectomy, a procedure associated with significant comorbidity, can be substituted with partial tonsillectomy in patients with recurrent tonsillitis. This paper is to present the 5-year follow-up data of our previous study titled “Total versus subtotal tonsillectomy for recurrent tonsillitis-a prospective randomized noninferiority clinical trial.” The underlying study was performed as single-blinded prospective noninferiority procedure in patients with recurrent chronic tonsil infection, where one side was removed completely (tonsillectomy) and the other side partially (intracapsular/partial tonsillectomy). Five years after surgery, we collected data on the frequency of tonsillitis in the first, second, third, fourth, and fifth year post-surgery. We obtained assessments from patients, their ENT physicians, and general practitioners separately. To assess the impact of surgical therapy on overall quality of life, we employed the Glasgow Benefit Inventory (GBI). Results: Out of the 111 patients initially included in the years 2015-2018, 79 were eligible for the 5-year follow-up, representing a 71% follow-up rate. The mean follow-up time was 60 months. Notably, during the first 12 months post-surgery, no cases of bacterial inflammation were observed in the remaining tonsillar tissue following partial tonsillectomy, suggesting noninferiority compared to total tonsillectomy. This effect remained consistent over the 5-year study period. GBI results indicate that both total and partial tonsillectomy positively impact the physical and mental health of patients with recurrent tonsillitis. Considering that partial tonsillectomy is associated with less pain and reduced postoperative bleeding, it may emerge as a potential replacement for total tonsillectomy as the standard method in the future.

Reference:

Kisser U, Stelter K, Lill C. Total versus subtotal tonsillectomy for recurrent tonsillitis: 5-year follow up of a prospective randomized noninferiority clinical trial. Eur Arch Otorhinolaryngol. 2024 Sep 26. doi: 10.1007/s00405-024-08987-1. Epub ahead of print. PMID: 39322860.

Keywords:

Partial, tonsillectomy, effective, total, tonsillectomy, patients, recurrent, tonsillitis, finds, study, Kisser U, Stelter K, Lill C, European Archives of Oto-Rhino-Laryngology, Tonsillectomy; Tonsillitis; Tonsillotomy

Powered by WPeMatico